{"prompt": "['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 21 of 92', 'CR845-CLIN3102', '4.0', 'Introduction', '4.1', 'Background and Rationale', 'CR845 is a kappa-opioid receptor (KOR) agonist with a peripheral mechanism of action', 'being developed by Cara Therapeutics, Inc. (designated as Cara Therapeutics or Sponsor', 'in this protocol) as a novel therapeutic agent for the symptomatic relief of acute and', 'chronic pain and pruritus.', 'Opioid receptors are involved in the modulation of itch and pain signals and consist of', '3 subtypes: mu, kappa, and delta. These receptor subtypes are found in the central', 'nervous system (CNS), in peripheral nervous system tissues, such as skin and viscera,', \"and in the immune system (see Investigator's Brochure for references and further details).\", 'CR845 was designed to activate KORs located primarily in the peripheral nervous', 'system, which are known to modulate itch, pain, and inflammatory signals, without', 'producing the side effects associated with the activation of mu-opioid receptors, such as', 'respiratory depression, abuse liability, and constipation.', 'CR845 is a potent and selective KOR agonist with no activity at mu- and delta-opioid', \"receptors or other receptors, ion channels, or transporters. CR845's unique peptidic\", 'structure significantly differs from other small molecule KOR agonists developed to date,', 'which, for the most part, are CNS-active. Being a hydrophilic peptide, CR845 has', 'limited membrane permeability by passive diffusion, which limits its access to the CNS.', 'Since CR845 does not activate receptors other than KORs and does not readily enter the', 'CNS, it is expected to be safer and better tolerated than other opioid agonists, including', 'kappa agonists.', 'Uremic pruritus is a chronic, unremitting, and highly bothersome condition in patients', 'with chronic kidney disease that adversely affects sleep, mood, and ability to socialize', '[Kumagai 2010]. Patients with uremic pruritus frequently exhibit considerable', 'mechanical skin damage because of continuous scratching with excoriations,', 'superimposed infections, and chronic lesions of prurigo nodularis or skin lichenification', 'often occurring. The mechanical skin damage can become an additional source of', 'itching. Consequently, these patients are at increased risk of related morbidities', 'associated with infection, eg, cellulitis, sepsis, bacteremia, cutaneous infections, and', 'infections of the dialysis access, and are at higher mortality risk (>15%)', '[Pisoni 2006; Narita 2006]. Large multinational studies (Dialysis Outcomes and Practice', 'Patterns) and studies based in the United States have demonstrated that approximately', '30 to 40% of hemodialysis patients have moderate-to-severe pruritus. There are no', 'approved treatments for this condition in the United States and current off-label therapies', 'are unable to successfully treat uremic pruritus.', 'Although the pathophysiology of moderate-to-severe pruritus in hemodialysis patients is', 'not well understood, there is increasing evidence that it is likely multifactorial and that an', 'immune system dysfunction (including elevated proinflammatory activity) and imbalance', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 23 of 95']['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 22 of 92', 'CR845-CLIN3102', 'in the endogenous opioid system (with over-expression of mu-opioid receptors in dermal', 'cells and lymphocytes and concomitant downregulation of KORs) are involved', '[Kimmel 2006; Narita 2006; Phan 2012; Patel 2007; Mettang 2002; Tey 2011].', 'Based on nonclinical pharmacological studies, it was anticipated that CR845 will produce', \"a combined anti-itch, and anti-inflammatory effect (see Investigator's Brochure for\", 'details), which could provide significant relief of itch in hemodialysis patients.', 'In nonclinical studies, CR845 has been shown to exhibit antipruritic and', \"anti-inflammatory properties [Investigator's Brochure]. Thus, CR845 is intended to\", 'reduce the severity of itching in hemodialysis patients and thereby decrease the likelihood', 'of developing additional serious conditions associated with uremic pruritus.', '4.2', 'Clinical Experience', '4.2.1', 'Overall Exposure', 'As of the writing of this protocol, the intravenous (IV) formulation of CR845 has been', 'evaluated in 722 patients and healthy volunteers across eight Phase 1 studies (including', '2 studies conducted in Japan), three Phase 2 studies for the relief of moderate-to-severe,', 'acute postoperative pain, and two Phase 2 studies for the relief of moderate-to-severe', 'pruritus in hemodialysis patients. In the United States, CR845 has been evaluated both as', 'an IV bolus and a 15-minute infusion of single or repeated doses ranging from', '0.5 to 40 mcg/kg.', 'Of the patients exposed to IV CR845 to date, 213 hemodialysis patients (127 males and', '86 females) have received single or repeated IV injections of CR845 doses (for up to', '8 weeks) ranging from 0.5 to 6 mcg/kg across two Phase 1 studies and two Phase 2 safety', 'and efficacy studies.', \"The most current information is contained in the current Investigator's Brochure.\", '4.2.2', 'Safety in Hemodialysis Patients', 'A review of the aggregate safety data shows that CR845 was well tolerated in', 'hemodialysis patients when administered after each dialysis session for up to 8 weeks at', 'IV doses ranging from 0.5 mcg/kg to 6 mcg/kg. Although patients exposed to CR845', 'reported more adverse events compared with placebo patients, most events were mild or', 'moderate in nature. Generally mild, transient paresthesias (facial tingling) and/or', 'hypoesthesias (in different anatomic locations), mostly on the first week of dosing, as', 'well as headache, dizziness, and somnolence, were the most frequently reported adverse', 'events associated with CR845 administration. Of note, side effects (eg, dysphoria and', 'hallucinations) commonly associated with centrally-acting kappa opioids were not', 'reported in patients exposed to CR845. Consistent with its lack of affinity for mu-opioid', 'receptors, CR845 did not cause euphoria, respiratory depression, or reduction in oxygen', 'saturation.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 24 of 95']\n\n###\n\n", "completion": "END"}